All 50 States Apply for New Medicaid Drug Pricing Model
The Trump administration's plan to bring most-favored-nation pricing to Medicaid has drawn participation requests from every state, according to the White House.
The Trump administration is rolling out a new Medicaid drug pricing model, and the White House says all 50 states have applied to take part. The model is designed to bring most-favored-nation pricing to Medicaid, a mechanism that would tie what the program pays for drugs to prices negotiated elsewhere.
Fierce Pharma's report, based on the White House announcement, does not include specifics on how the model would be implemented, what drugs it would cover, or how it would interact with existing Medicaid rebate rules. No timeline or cost estimates are provided.
The reported participation of every state suggests broad interest in the approach, but the source relies solely on the White House's statement. Independent confirmation and further policy details would be needed to assess the model's potential impact on drug pricing and patient access.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.